IL17RA and colitis: Intestinal mucosal inflammation is considered to be an important player in the occurrence and development of UC, and it has become a key target for developing innovative anti‐colitis drugs.[10] Recently, multitudinous studies have focused on the critical effect of IL‐17 signaling on immune‐inflammation related diseases.[11, 12] The IL‐17 receptor (IL‐17R) family consists of five subunits, from IL‐17 receptor A (IL‐17RA) to receptor E (IL‐17RE).